preloader
logologo
  • About Us
    • B+E Team
    • Our Services
    • Join Our Team
    • Contact Us
  • BUY
  • SELL
  • 1031 TRADE
  • INSIGHTS
    • Sale Leaseback
    • Tax Advantages
    • Net Lease Guide
  • Subscribe

Subscribe
LOGIN | REGISTER

logologo
  • About Us
    • B+E Team
    • Our Services
    • Join Our Team
    • Contact Us
  • BUY
  • SELL
  • 1031 TRADE
  • INSIGHTS
    • Sale Leaseback
    • Tax Advantages
    • Net Lease Guide
  • Subscribe

Subscribe
LOGIN | REGISTER

logologo
  • About Us
    • B+E Team
    • Our Services
    • Join Our Team
    • Contact Us
  • BUY
  • SELL
  • 1031 TRADE
  • INSIGHTS
    • Sale Leaseback
    • Tax Advantages
    • Net Lease Guide
  • Subscribe

Subscribe
LOGIN | REGISTER

logologo
  • About Us
    • B+E Team
    • Our Services
    • Join Our Team
    • Contact Us
  • BUY
  • SELL
  • 1031 TRADE
  • INSIGHTS
    • Sale Leaseback
    • Tax Advantages
    • Net Lease Guide
  • Subscribe

Subscribe
LOGIN | REGISTER

  • About Us
    • B+E Team
    • Our Services
    • Join Our Team
    • Contact Us
  • BUY
  • SELL
  • 1031 TRADE
  • INSIGHTS
    • Sale Leaseback
    • Tax Advantages
    • Net Lease Guide
  • Subscribe
Tenant Profiles

DaVita Dialysis

B+E > B+E INSIGHTS > Tenant Profiles > DaVita Dialysis
02/29/2024 By B+E

Davita Dialysis

davita.com

21
Number on Market

$3.4
Average Price

7.6
Average Remaining Term (Years)

6.12%
Average Cap Rate

Davita Tenant Overview

DaVita Inc. is a Fortune 500 company and the parent company of DaVita Kidney Care and DaVita Medical Group. DaVita Kidney Care is the leading provider of kidney care in the United States, with 2,510 outpatient dialysis centers serving around 198,000 patients. Additionally, the company operates 237 outpatient dialysis centers in 11 countries outside of the United States. DaVita employs over 70,800 individuals and provides care for more than 1.7 million patients. It has been recognized on Fortune’s World’s Most Admired Companies list for ten consecutive years.

davita

Tenant Data:

Company Davita Dialysis
Ownership Public
Headquarters Denver, CO
Ticker NYSE: DVA
Credit Rating BB (S&P)
Annual Revenue $11.6B (FY 2022)
Locations ± 2,747
Website www.davita.com
Average Davita Dialysis Info
Number on Market 21
Average Price $3,366,722
Average Remaining Term 7.6 Years
Average Cap Rate 6.12%
Average NOI $192,780
Average PPSF $396
Average Building SF 12,534 SF
Average Lot Size 1.34 AC
AS OF 02/01/2024

Featured Listings:

Kavitha
Available
Dallas, TX

Kavitha

Medical
  • 0.00%
  • 4yrs & 4mo
  • AAA
  • $679,675
Zudio -Angular 1
Available
New York, NY

Zudio -Angular 1

Retail
  • 0.00%
  • Expired
  • AAA
  • $29,681,000
Zudio- June 24
Available
San Francisco, CA

Zudio- June 24

Industrial , 3+
  • 9.29%
  • 6yrs & 8mo
  • -
  • $4,555,555
Portfiloooooo
Available
11 11
California, Georgia , 6+

Portfiloooooo

Color , 4+
  • 0.06%
  • 4yrs & 5mo
  • -
  • $5,877,523,310

Latest Insights:

Brokers Ready For A Post-Rate-Cut World

Test post 4 – sale leaseback

Excerpt section
Read More »
B+E Brokers Sale of Portland FedEx Property for $32M

Test Post 2 – Net lease guide

Excerpt section
Read More »
shell gas station

Test Post 1- Net lease guide

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin rhoncus quam vel nunc vestibulum, vitae fermentum libero malesuada.Lorem ipsum dolor sit amet, consectetur adipiscing
Read More »

Categories

  • Sale Leaseback
  • Net Lease Guide
  • B+E Research and Insights
  • Tenant Profiles
  • News
  • Closings
  • Conferences
  • Articles

LinkedIn Feed

B+E | Net Lease Brokerage | 1031 Exchanges

B+E is a modern investment brokerage firm, specializing in net lease real estate and 1031 exchanges.

Quick Links

  • Home
  • Buy
  • Sell
  • 1031 Trade
  • B+E Insights
  • Privacy Policy
  • Terms and Conditions

About Us

  • B+E Team
  • Our Services
  • Join Our Team
  • Contact Us

info@tradenetlease.com

646-770-0659

41 Madison Ave, Floor 31, New York, NY 10010





Email Preferences

Copyright ©2024 B+E

Keep me posted on the latest B+E Listings, News, and Research.